TY - JOUR T1 - Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers JF - medRxiv DO - 10.1101/2022.10.18.22281172 SP - 2022.10.18.22281172 AU - Pete Schmidt AU - Kristin Narayan AU - Yong Li AU - Chengzi I. Kaku AU - Michael E. Brown AU - Elizabeth Champney AU - James C. Geoghegan AU - Maximiliano Vásquez AU - Eric M. Krauland AU - Thomas Yockachonis AU - Shuangyi Bai AU - Bronwyn M. Gunn AU - Anthony Cammarata AU - Christopher M. Rubino AU - Laura M. Walker Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/10/19/2022.10.18.22281172.abstract N2 - Multiple studies of vaccinated and convalescent cohorts have demonstrated that serum neutralizing antibody (nAb) titers correlate with protection against COVID-19. However, the induction of multiple layers of immunity following SARS-CoV-2 exposure has complicated the establishment of nAbs as a mechanistic correlate of protection (CoP) and hindered the definition of a protective nAb threshold. Here, we show that a half-life extended monoclonal antibody (adintrevimab) provides approximately 50% protection against symptomatic COVID-19 in SARS-CoV-2-naïve adults at low serum nAb titers on the order of 1:30. Vaccine modeling supports a similar 50% protective nAb threshold, suggesting low levels of serum nAb can protect in both monoclonal and polyclonal settings. Extrapolation of adintrevimab pharmacokinetic data suggests that protection against susceptible variants could be maintained for approximately 3 years. The results provide a benchmark for the selection of next-generation vaccine candidates and support the use of broad, long-acting monoclonal antibodies as an alternative or supplement to vaccination in high-risk populations.Competing Interest StatementL.M.W., P.S., K.N., and Y.L., are employees of Invivyd, Inc and hold shares in Invivyd, Inc.Clinical TrialNCT04859517Funding StatementB.M.G. and J.M.D. were supported by NIH/NIAID grant 5U19AI142777.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by Advarra Central IRB in the US and by the local IRBs of other participating countriesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAntibody sequences have been deposited in GenBank under accession codes MZ439266-MZ439267. IgGs are available from the corresponding author under MTA from Invivyd, Inc. All other data is available in the manuscript or supporting material. ER -